$CLDI News

Last published 2w ago

2w agoCLDICalidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE BiofactoriesGlobeNewswireSingle-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the
3w agoCLDICalidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026GlobeNewswireSAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines,
1mo agoCLDICalidi Biotherapeutics Announces $1.2 Million Registered Direct OfferingGlobeNewswireSAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines,
2mo agoCLDICalidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines,
3mo agoCLDICalidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireReceived positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the
3mo agoCLDICalidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development ConferenceGlobeNewswireSAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically
3mo agoCLDICalidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value DriversGlobeNewswireCompany receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first patient in Q1
3mo agoCLDICalidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026GlobeNewswireSAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a biotechnology company pioneering the development of targeted genetic medicine,
4mo agoCLDICalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711GlobeNewswireSAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in
4mo agoCLDICalidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic SummitGlobeNewswireSAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines,
4mo agoCLDI LEGN RARECalidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of DirectorsGlobeNewswireSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines,
4mo agoCLDICalidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human StudyGlobeNewswireSAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announces that
5mo agoCLDICalidi Biotherapeutics Announces Investor Webinar on June 9, 2026GlobeNewswireSAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, will participate in
5mo agoCLDICalidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual MeetingGlobeNewswireSAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced that two
5mo agoCLDICalidi Biotherapeutics Provides Required NYSE American DisclosureGlobeNewswireSAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today advised that its
6mo agoCLDICalidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational HighlightsGlobeNewswirePresented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026Presented new
6mo agoCLDICalidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in BostonGlobeNewswireSAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a
6mo agoCLDICalidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AIGlobeNewswireSAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, announced today that
6mo agoCLDICalidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026GlobeNewswireSAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) – Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of
6mo agoCLDICalidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026GlobeNewswireSAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, presented new data
7mo agoCLDICalidi Biotherapeutics Announces Participation in RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsGlobeNewswireSAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will participate in
7mo agoCLDICalidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic TherapyGlobeNewswireSAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present at the
7mo agoCLDICalidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic TherapyGlobeNewswireSAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new
7mo agoCLDICalidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026GlobeNewswireSAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new
7mo agoCLDICalidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026GlobeNewswireSAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new
7mo agoCLDICalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational HighlightsGlobeNewswireAnnounced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and
7mo agoCLDICalidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical TrialsGlobeNewswireSAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced a
8mo agoCLDICalidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionGlobeNewswireSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the
8mo agoCLDICalidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public OfferingGlobeNewswireSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the
8mo agoCLDICalidi Biotherapeutics Announces Proposed Public OfferingGlobeNewswireSAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced that
8mo agoCLDICalidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO ConferenceGlobeNewswireSAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data
9mo agoCLDICalidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO ConferenceGlobeNewswireSAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced that
9mo agoCLDICalidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026GlobeNewswireCompany intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor
11mo agoCLDICalidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025GlobeNewswireSAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
12mo agoCLDICalidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational HighlightsGlobeNewswirePresented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively
1y agoCLDICalidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITCGlobeNewswireSAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted
1y agoCLDICalidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual MeetingGlobeNewswireSAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted
1y agoCLDIMatica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward INDPR NewswireMatica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a strategic partnership...
1y agoCLDICalidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual MeetingGlobeNewswireSAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted
1y agoCLDICalidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic MedicineGlobeNewswireSAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted
1y agoCLDICalidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in BostonGlobeNewswireSAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc.
1y agoCLDICalidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
1y agoCLDICalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionGlobeNewswireSAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
1y agoCLDICalidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public OfferingGlobeNewswireSAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
1y agoCLDICalidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational HighlightsGlobeNewswirePresented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through
1y agoCLDICalidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue SarcomaGlobeNewswireSAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
1y agoCLDICalidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025GlobeNewswireSAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
1y agoCLDIJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24GlobeNewswireSAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the
1y agoONCY KZIA IMRX NUVB+1Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step UpPR NewswireUSA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data,...
1y agoCLDICalidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer TreatmentGlobeNewswireNEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE:CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands